| Organization and levels of Newborn care (DNB 2006/1)10 | 114 | 2006 |
| Setting up of special care newborn unit in a district hospital (DNB 2017/1)5 | 114 | 2017 |
| Special Newborn Care Unit (DNB 2024/2)5 | 114 | 2024 |
| Predicting neonatal mortality scoring systems (DNB 2019/2)6 | 114 | 2019 |
| Endocrine problems that can be diagnosed on the first day of life (DNB 1995/1)10 | 115 | 1995 |
| Kidney functions in neonate (DNB 1998/2)(DNB 1999/2)10 | 115 | 1998 |
| Diagrammatic depiction of layers of scalp and their relationship to various haemorrhages in new born scalp (DNB 2000/1)10 | 115 | 2000 |
| List the key problems during breast feeding and their management (DNB 2000/2)10 | 115 | 2000 |
| Probiotics in neonates (DNB 2015/1)5 | 115 | 2015 |
| Screening for birth defects at delivery points (DNB 2019/2)4 | 115 | 2019 |
| Delayed cord clamping in neonates (DNB 2022/2)4 | 115 | 2022 |
| Cord care in term neonates (DNB 2022/2)3 | 115 | 2022 |
| Cord milking: current guideline and controversies (DNB 2024/2)5 | 115 | 2024 |
| Assessment of gestational age of newborn (DNB 2024/1)5 | 115 | 2024 |
| Thermoregulation peculiarities in newborn (DNB 1994/2)15 | 115 | 1994 |
| Hypothermia in the newborn (DNB 1997/1)15 | 115 | 1997 |
| Thermal regulation in newborn (DNB 1998/2)10 | 115 | 1998 |
| Prevention of Hypothermia in the newborn (DNB 1998/2)15 | 115 | 1998 |
| Physiological and biochemical consequences of Hypothermia in Neonate (DNB 1999/1)15 | 115 | 1999 |
| Thermal balance in Neonates (DNB 2003/2)15 | 115 | 2003 |
| Discuss management of Neonatal Hypothermia (DNB 2006/2)5 | 115 | 2006 |
| Write the components, pre-requisites and benefits of Kangaroo Mother care (DNB 2008/2)10, (DNB 2011/2)5+2+3 | 115 | 2008 |
| Discuss the principles of care of the skin in neonates. Outline the role of touch and massage therapy in newborn infants (DNB 2010/2)4+3+3 | 115 | 2010 |
| Describe the advantages and methods of giving Kangaroo Mother Care (KMC). Enlist metabolic consequences of hypothermia (DNB 2013/1)4+4+2 | 115 | 2013 |
| Hypothermia in newborn (DNB 2016/2)5 | 115 | 2016 |
| Temperature regulation in newborns (DNB 2018/2)5 | 115 | 2018 |
| Components and benefits of KMC (DNB 2018/2)5 | 115 | 2018 |
| What is Kangaroo mother care? Enumerate its advantage (DNB 2019/1)5 | 115 | 2019 |
| Kangaroo Mother Care for care of newborn (DNB 2024/1)5 | 115 | 2024 |
| Physiology of thermal control in newborn babies (DCH 2024/1)5 | 115 | 2024 |
| Warm chain in neonate (DCH 2024/1)5 | 115 | 2024 |
| Scheme for identifying High Risk Fetuses (DNB 1992/2)15 | 116 | 1992 |
| Discuss the basic elements of the 'At Risk' concept with regard to their advantages and disadvantages and fallacies if any as they relate to health care of mothers and children (DNB 1995/2)25 | 116 | 1995 |
| Placental dysfunction syndrome (DNB 1995/2)15 | 116 | 1995 |
| Complications of infants born to diabetic mothers (DNB 2007/2)10 | 116 | 2007 |
| Amniocentesis in prenatal diagnosis (DNB 1992/1)15 | 117 | 1992 |
| Intrauterine Diagnosis (DNB 1993/2)10 | 117 | 1993 |
| Discuss the methods of detection of congenital malformations in the fetus and their prevention (DNB 1995/1)25 | 117 | 1995 |
| Antenatal Diagnosis (DNB 1998/2)10 | 117 | 1998 |
| Methods to diagnose fetal disorder. Fetal medical therapy (DNB 2005/1)5+5 | 117 | 2005 |
| List various methods for Fetal diagnosis and assessment along with indications (DNB 2006/1) 5 | 117 | 2006 |
| Prenatal Diagnosis and Fetal therapy (DNB 2006/1)10 | 117 | 2006 |
| What are the methods of diagnosis of fetal disorders? Describe the fetal medical and surgical therapeutic options for various fetal disorders (DNB 2009/2)10 | 117 | 2009 |
| Antenatal screening for Down syndrome (DNB 2013/1)5 | 117 | 2013 |
| Outline the methods of assessing fetal wellbeing with their clinical indications (DNB 2013/2)5 | 117 | 2013 |
| Describe in detail tests for antepartum and intrapartum monitoring of fetal distress (DNB 2006/2)5 | 117 | 2006 |
| Fetal monitoring (DNB 2006/1)10 | 117 | 2006 |
| Discuss the complications in the fetus and newborn of a mother with diabetes during pregnancy (DNB 2008/1)10 | 117 | 2008 |
| Assessment of fetal wellbeing in pregnancy (DNB 2017/2)6 | 117 | 2017 |
| Maternal factors affecting fetal growth (DNB 2017/2)4 (DCH 2024/1)5 | 117 | 2017 |
| Antenatal screening (DNB 2019/2)4 | 117 | 2019 |
| Chorionic villi sampling - method, indications and complications (DNB 2019/2)2+2+2 | 117 | 2019 |
| Antenatal diagnosis of neural tube defects (DNB 2021/1)5 | 117 | 2021 |
| Antenatal diagnosis of congenital malformations (DNB 2021/2)5 | 117 | 2021 |
| Antenatal monitoring of fetal well being (DNB 2022/2)5 | 117 | 2022 |
| Amniocentesis (DNB 2023/2)5 | 117 | 2023 |
| Cell-free DNA prenatal screening test (DNB 2024/2)5 | 117 | 2024 |
| Prenatal steroid therapy (DNB 1999/2)15 | 118 | 1999 |
| Treatment and prevention of fetal diseases (DNB 2007/1)10 | 118 | 2007 |
| Medical management of Fetal Problems (DNB 2007/2)10 | 118 | 2007 |
| Fetal Therapy (DNB 2003/2)15 | 118 | 2003 |
| Steroid in neonatal care (DNB 2007/1)5 | 118 | 2007 |
| Intrauterine fetal therapy (DNB 2019/1)5 | 118 | 2019 |
| Fetal therapy (DNB 2016/1)5, (DNB 2021/2)5 | 118 | 2016 |
| Fetal surgical therapy (DNB 2021/2)5 | 118 | 2021 |
| Fetal surgery (DNB 2022/1)5 | 118 | 2022 |
| Intrauterine transfusion (DNB 2022/1)5 | 118 | 2022 |
| Define 'High risk infant'. Discuss the long term management of such infants with emphasis on detection and early intervention of infants with developmental disabilities (DNB 1995/1)25 | 119 | 1995 |
| Fluid therapy in special situations in neonates (DNB 2006/1)10 | 119 | 2006 |
| A) What is Developmentally supportive care B) Components of developmentally supportive care in neonates (DNB 2015/2)3+7 | 119 | 2015 |
| Developmentally supportive care in neonates (DNB 2015/1)3 | 119 | 2015 |
| Triage of sick newborn who is admitted in SCNU (DNB 2018/2)5 | 119 | 2018 |
| Enumerate the criteria of discharge of LBW baby from SCNU (DNB 2019/1)5 | 119 | 2019 |
| Surgical emergencies in newborn (DNB 2020/2)5 | 119 | 2020 |
| Follow up of a NICU graduate (DNB 2024/2)5 | 119 | 2024 |
| Factors associated with IUGR (DNB 1993/1)10 | 119 | 1993 |
| Immune status of SFD babies (DNB 1998/1)15 | 119 | 1998 |
| List the principles of community care of LBW infants. Define Kangaroo Mother care. Outline its advantages and disadvantages (DNB 2004/2)4+2+4 | 119 | 2004 |
| Outline the handicaps in enteral feeding of LBW newborns. Briefly discuss the feeding strategies for LBW babies (DNB 2004/2)3+4+3 | 119 | 2004 |
| Enumerate the etiology of fetal or intrauterine growth retardation (IUGR). Describe the screening and diagnosis of IUGR (DNB 2011/2)3+4+3 | 119 | 2011 |
| Immediate and late problems due to low birth weight (DNB 2013/1)5 | 119 | 2013 |
| Feeding of low birth weight babies (DNB 2015/1)5 | 119 | 2015 |
| Interventions to improve neurodevelopmental outcome of LBW infants at 1 year of age (DNB 2017/2)6 | 119 | 2017 |
| Enumerate the socio-demographic factors associate with Low birth weight babies. Discuss the clinical problems of Preterm babies (DNB 1996/1)25 | 119 | 1996 |
| Pharmacotherapy in prematurity clinical decisions salient features (DNB 2003/1)15 | 119 | 2003 |
| Management of Patent Ductus Arteriosus (PDA) in preterm neonates (DNB 2010/1)10 | 119 | 2010 |
| Enumerate the factors associated with prematurity and low birth weight. Discuss the potential pathways by which infection plays a role in premature delivery (DNB 2013/1)4+6 | 119 | 2013 |
| Describe the development of the ductus arteriosus. Enumerate the duct dependent lesions in the newborn and outline their management (DNB 2014/1)3+2+5 | 119 | 2014 |
| Physical difference between preterm and IUGR neonates (DNB 2017/2)4 | 119 | 2017 |
| Management of premature baby in labour room (DNB 2021/2)5 | 119 | 2021 |
| Late preterm neonates and their problems (DNB 2022/2)5 | 119 | 2022 |
| Complications of prematurity (DCH 2024/1)5 | 119 | 2024 |
| Osteopenia of prematurity (DNB 2006/1)10 (DNB 2024/2)5 | 119 | 2006 |
| Probable complications in monozygotic twins (DNB 2022/1)5 | 119 | 2022 |
| Write short notes on: Trophic feeding (DNB 2013/1)5 | 119 | 2013 |
| Discuss attributes, complications and monitoring of total parenteral nutrition in a newborn (DNB 2013/1)5 | 119 | 2013 |
| Write short notes on: a. Human Milk Fortifiers b. Vitamin D supplementation in neonates c. Medium chain triglycerides in neonatal nutrition (DNB 2014/1)4+3+3 | 119 | 2014 |
| Minimal enteral nutrition for low birth weight babies (DNB 2019/1)5 | 119 | 2019 |
| Nutritional requirements of preterm babies (DNB 2019/1)5 | 119 | 2019 |
| Non-nutritive sucking and early infant stimulation (DNB 2019/2)5 | 119 | 2019 |
| Human Milk Fortifiers (DNB 2024/1)5 | 119 | 2024 |
| Anti-infective properties of human milk (DNB 2024/1)5 | 119 | 2024 |
| Discuss the principles of safe and stable transport of a sick newborn (DNB 2013/1)10 | 120 | 2013 |
| Issues related to transport of sick newborn (DNB 2014/2)5 | 120 | 2014 |
| Transport of a sick newborn (DNB 2022/1)5 | 120 | 2022 |
| Transport of the critically ill newborn (DNB 2023/2)5 | 120 | 2023 |
| Foetal circulation and changes at birth (DNB 2000/1)15 | 121 | 2000 |
| Cyanosis in newborn (DNB 2016/1)5 | 121 | 2016 |
| Enumerate common peripheral nerve injuries in neonates. Describe their clinical characteristics and outline the management (DNB 2009/1)2+3+5 | 122 | 2009 |
| HIE (DNB 1993/1)15, (DNB 1992/2)15 | 122 | 1993 |
| Prognosis of Birth Asphyxia (DNB 1993/1)10 | 122 | 1993 |
| HIE in newborn (DNB 1995/1)10 | 122 | 1995 |
| Discuss the etiopathology and management of birth asphyxia (DNB 1996/2)25 | 122 | 1996 |
| HIE (DNB 1997/2)15 | 122 | 1997 |
| Clinical and laboratory correlates of neuromotor outcome in Birth asphyxia (DNB 1997/1)10 | 122 | 1997 |
| Discuss briefly pathophysiology and recent modalities of management of HIE (DNB 1999/2)15 | 122 | 1999 |
| Perinatal asphyxia - clinical features and management (DNB 2002/1)15 | 122 | 2002 |
| What are the etiological causes of Fetal Hypoxia? Write pathophysiology of Fetal Hypoxia. Describe stages of HIE (DNB 2006/1)10 | 122 | 2006 |
| Pathophysiology of Hypoxic Brain injury in neonate (DNB 2006/1)10 | 122 | 2006 |
| Discuss the pathophysiology of hypoxic Ischemic Encephalopathy (HIE) in neonates (DNB 2009/1)10 | 122 | 2009 |
| Discuss etiology, pathophysiology, clinical manifestations and management of HIE (DNB 2013/2)10 | 122 | 2013 |
| Neuroprotective strategies in CNS injuries in neonates (DNB 2015/2)5 | 122 | 2015 |
| Clinical features and management of HIE (DNB 2016/2)5 | 122 | 2016 |
| Selective hypothermia for management of HIE (DNB 2019/1)5 | 122 | 2019 |
| Therapeutic hypothermia (DNB 2020/1)5, (DNB 2023/2)5 | 122 | 2020 |
| Staging & management hypoxic ischemic encephalopathy (HIE) (DNB 2020/2)5 | 122 | 2020 |
| Therapeutic hypothermia for hypoxic ischemic encephalopathy for neonates born in low and middle-income settings (DNB 2022/2)5 | 122 | 2022 |
| Therapeutic hypothermia in pediatric population (DNB 2024/2)5 | 122 | 2024 |
| Management of Hypoxic ischemic encephalopathy in neonate (DNB 2024/1)5 | 122 | 2024 |
| Stages of hypoxic ischaemic encephalopathy (DCH 2024/1)5 | 122 | 2024 |
| Newer modalities of treatment of birth asphyxia (DCH 2024/1)5 | 122 | 2024 |
| Etiopathogenesis of neonatal seizures (DNB 2002/1)15 | 122 | 2002 |
| Management of Resistant Neonatal Seizure (DNB 2003/2)15 | 122 | 2003 |
| Classify neonatal seizures. Outline their etiology and provide a brief clinical description. Provide general principles of management of a seizure in neonate (DNB 2012/1)2+2+3+3 | 122 | 2012 |
| Investigation and treatment of neonatal seizure (DNB 2018/2)7 | 122 | 2018 |
| Approach to child with seizure in day 2 of life (DNB 2019/2)5 | 122 | 2019 |
| Management of neonatal seizures (DNB 2020/2)5 | 122 | 2020 |
| Current classification and management of neonatal seizures (DNB 2024/2)5 | 122 | 2024 |
| IVH (DNB 2003/1)15 | 122 | 2003 |
| Outline the risk factors, pathophysiology and principles of management of intraventricular hemorrhage in preterm neonates (DNB 2010/2)3+3+4 | 122 | 2010 |
| Discuss the pathogenesis of intracranial hemorrhage in newborn infants. Outline the possible promoters and protectors for occurrence of subsequent white matter disease (DNB 2012/1)6+2+2 | 122 | 2012 |
| Pathophysiology and management of intraventricular hemorrhage (DNB 2015/2)5 | 122 | 2015 |
| Steps in Neonatal Resuscitation (DNB 2000/1)15 | 123 | 2000 |
| How do you assign APGAR score to a neonate. In which 5 conditions will you get a low score without associated hypoxia? What are fallacies of APGAR score (DNB 2006/1)10 | 123 | 2006 |
| What is the sequence of events leading to the first breath after Delivery? What is the Significance of establishment of Functional Residual Capacity? (DNB 2006/1)10 | 123 | 2006 |
| A term baby is apnoeic. What information of the perinatal events you would like to know? What are the initial steps of management in the labor room? What are the possible complications in the next 48 hours? (DNB 2008/2)10 | 123 | 2008 |
| Describe the changes taking place in circulation at birth and their implications in neonatal resuscitation (DNB 2009/1)5+5 | 123 | 2009 |
| Enumerate the newer recommendations of neonatal resuscitation by American Academy of Pediatrics 2010 guidelines. Comment on the level of evidence for each of the changes (DNB 2012/1)6+4 | 123 | 2012 |
| Discus the recent changes in guidelines for resuscitation of new born and older children with the rationale for the change (DNB 2013/1)10 | 123 | 2013 |
| Recent NRP guidelines (DNB 2019/1)5 | 123 | 2019 |
| Algorithm of neonatal resuscitation programme (NRP) (DNB 2020/2)5 | 123 | 2020 |
| Pathophysiology of Apnea Of Prematurity (DNB 1997/2)15 | 125 | 1997 |
| A 10-day old preterm neonate has recurrent cessation of breathing lasting for more than 20 seconds with bradycardia. Classify and enumerate causes for this condition. Discuss in brief the management of this condition (DNB 2012/1)4+6 | 125 | 2012 |
| Management of neonatal apnea (DNB 2013/1)5 | 125 | 2013 |
| Apnea of Prematurity (DNB 2016/2)5 | 125 | 2016 |
| Apnea of Prematurity (DNB 2023/2)5 | 125 | 2023 |
| Pathophysiology of RDS of newborn (DNB 1994/1)15 | 126 | 1994 |
| Tests for pulmonary maturity and surfactant therapy for RDS (DNB 1994/2)15 | 126 | 1994 |
| Surfactant therapy (DNB 1998/1)10 | 126 | 1998 |
| Surfactant therapy for HMD (DNB 1998/2)15 | 126 | 1998 |
| Discuss RDS with special reference to surfactant therapy (DNB 1999/2)15 | 126 | 1999 |
| HMD- pathophysiology and management (DNB 2003/1)25 | 126 | 2003 |
| List the causes of respiratory distress in preterms. Outline the principles of surfactant therapy in preterms. Outline the manifestations of oxygen therapy in newborns (DNB 2004/2)2+4+4 | 126 | 2004 |
| Etiology, pathogenesis and management of a neonate with RDS (DNB 2006/1)10 | 126 | 2006 |
| Briefly discuss normal fetal development of Surfactant. List the uses of Surfactant in newborn (DNB 2007/2)10 | 126 | 2007 |
| Discuss the pathophysiology of hyaline membrane disease in premature newborns (DNB 2010/2)10 | 126 | 2010 |
| Describe the pathophysiology of hyaline membrane disease (HMD) in newborns. Outline important available strategies to prevent HMD (DNB 2011/1)5+5 | 126 | 2011 |
| A) CPAP for neonatal RDS B) Surfactant replacement therapy (DNB 2015/1)5+5 | 126 | 2015 |
| INSURE therapy in neonates (DNB 2014/1)5 | 126 | 2014 |
| Surfactant replacement therapy (DNB 2017/1)5 | 126 | 2017 |
| Differential diagnosis of respiratory distress in 6 hours old new-born infant (DNB 2017/1)4 | 126 | 2017 |
| Pathophysiology and recent advances in the management of RDS (DNB 2017/1)6 | 126 | 2017 |
| Surfactant in hyaline membrane disease (DNB 2018/1)5 | 126 | 2018 |
| Enumerate the indications and technique of surfactant therapy (DNB 2019/1)5 | 126 | 2019 |
| Approach to a newborn with respiratory distress (DNB 2020/2)5, (DCH 2024/1)5 | 126 | 2020 |
| Minimally invasive surfactant therapy (DNB 2021/1)5, (DNB 2022/2)5 | 126 | 2021 |
| Types of Surfactants used in neonates (DNB 2022/1)5 | 126 | 2022 |
| Strategies of weaning from mechanical ventilation in a preterm neonate with respiratory distress syndrome (DNB 2022/2)5 | 126 | 2022 |
| Respiratory distress in newborn and its causes (DCH 2023/2)5 | 126 | 2023 |
| Surfactant therapy in HMD (DCH 2023/2)5 | 126 | 2023 |
| Evidence based management of hyaline membrane disease (DCH 2024/1)5 | 126 | 2024 |
| Describe the pathophysiology of respiratory distress syndrome (RDS) (DNB 2024/2)4 | 126 | 2024 |
| Outline the respiratory support and ventilation strategy for RDS (DNB 2024/2)3 | 126 | 2024 |
| What are the types of surfactants available for the treatment of RDS? (DNB 2024/2)3 | 126 | 2024 |
| Define ARDS and briefly describe its management in pediatric population (DNB 2024/2)5 | 126 | 2024 |
| BPD (DNB 1997/1)15 | 127 | 1997 |
| Outline and discuss the strategies to prevent lung injury and bronchopulmonary dysplasia in a preterm baby (DNB 2013/1)10 | 127 | 2013 |
| Management of Bronchopulmonary Dysplasia (DNB 2021/1)5 | 127 | 2021 |
| Prevention of Bronchopulmonary dysplasia (DNB 2023/2)5 | 127 | 2023 |
| Meconium Aspiration Syndrome (DNB 1997/2)15 | 129 | 1997 |
| Discuss the pathogenesis and management of MAS (DNB 2000/1)25 | 129 | 2000 |
| Delivery room management of a term baby born through meconium stained liquor (DNB 2022/2)5 | 129 | 2022 |
| Describe in brief PPHN (or PFC) with regard to Pathology, pathophysiology, Diagnosis and management (DNB 1994/2)25 | 130 | 1994 |
| What is the etiopathogenesis of PPHN of Newborn. Outline the diagnosis and management (DNB 2005/1)3+3+4 | 130 | 2005 |
| PPHN (DNB 2006/1)10 | 130 | 2006 |
| Discuss the diagnosis and management of PPHN (DNB 2007/2)10 | 130 | 2007 |
| Enumerate causes of persistent pulmonary hypertension in neonates and discuss its pathophysiology (DNB 2008/1)10 | 130 | 2008 |
| Discuss the approach to diagnosis of Persistent Pulmonary Hypertension of Newborn (PPHN). Outline the available modalities of management, highlighting their key features in a tabular format (DNB 2010/2)4+6 | 130 | 2010 |
| Etiology and management of persistent pulmonary hypertension (DNB 2014/2)3+7 | 130 | 2014 |
| Pathophysiology of persistent fetal circulation (DNB 2015/1)3 | 130 | 2015 |
| INO therapy in PPHN (DNB 2019/1)5 | 130 | 2019 |
| Persistent pulmonary hypertension (PPHN) (DNB 2019/2)5 | 130 | 2019 |
| Describe the management of Primary Pulmonary Hypertension (DNB 2022/1)5 | 130 | 2022 |
| PPHN and its management (DCH 2023/2)5 | 130 | 2023 |
| Describe the surgical causes of respiratory difficulty in newborn (DNB 2002/1)25 | 131 | 2002 |
| Write notes on embryological development of abdominal diaphragm and types of congenital diaphragmatic hernia (DNB 2006/1)10 | 131 | 2006 |
| Current recommendations for management of Congenital diaphragmatic hernia (DNB 2022/1)5 | 131 | 2022 |
| Fetal intervention for an antenatally diagnosed Congenital Diaphragmatic Hernia (DNB 2024/2)5 | 131 | 2024 |
| Describe the development of the midgut. Enumerate the causes for bilious vomiting in a two- week old neonate and discuss its management (DNB 2014/1)3+2+5 | 134 | 2014 |
| Pathogenesis of NEC (DNB 1997/1)15 | 136 | 1997 |
| NEC (DNB 1997/2)15 | 136 | 1997 |
| Etiology and pathology of NEC (DNB 1998/2)15 | 136 | 1998 |
| Etiology of NEC, staging and management (DNB 2004/2)10 | 136 | 2004 |
| Discuss management of NEC (DNB 2006/1)5 | 136 | 2006 |
| Discuss the clinical features, diagnosis and management of neonatal necrotizing enterocolitis (DNB 2009/1)3+7 | 136 | 2009 |
| Discuss the pathophysiology, classification and diagnostic features of necrotizing enterocolitis. (DNB 2010/2)4+3+3 | 136 | 2010 |
| A 6-day old preterm neonate presents with abdominal distension, feed intolerance, vomiting and blood in stools. Discuss the differential diagnosis, diagnostic approach and principles of initial stabilization (DNB 2012/1)4+3+3 | 136 | 2012 |
| Necrotizing Enterocolitis (NEC) - etiology, staging and management (DNB 2020/1)5 | 136 | 2020 |
| Probiotics for prevention of neonatal necrotizing enterocolitis (DNB 2024/1)5 | 136 | 2024 |
| Neonatal necrotizing enterocolitis: a) Risk factors b) Pathogenesis c) Treatment (DCH 2024/2)3+3+4 | 136 | 2024 |
| Pathogenesis of kernicterus (DNB 1996/2)10 | 137 | 1996 |
| A 3-week old infant brought to the hospital with moderate jaundice. Discuss the Diagnosis (DNB 1997/2)10 | 137 | 1997 |
| Kernicterus (DNB 1997/1)15 | 137 | 1997 |
| Discuss the Bilirubin metabolism and list the causes and approach to diagnosis of Hyperbilirubinemia in a neonate (DNB 2000/1)15 | 137 | 2000 |
| Discuss reasons for Physiological Jaundice in a Newborn. Define and list causes of pathological jaundice in a newborn. Discuss clinical manifestations (acute and chronic) of kernicterus (DNB 2006/1)10 | 137 | 2006 |
| Outline the normal metabolism of bilirubin. Outline the principle of phototherapy for treatment of neonatal jaundice. List factors that influence efficacy of phototherapy (DNB 2008/1)10, (DNB 2009/1)10, (DNB 2010/2)4+3+3 | 137 | 2008 |
| Critically describe the role of various treatment modalities for treating neonatal unconjugated hyperbilirubinemia (DNB 2011/2)10 | 137 | 2011 |
| Outline and discuss various strategies to manage hyperbilirubinemia in newborns (DNB 2013/1)10 | 137 | 2013 |
| Short note on side effects of phototherapy (DNB 2014/2)5 | 137 | 2014 |
| Complications of unconjugated hyperbilirubinemia in a neonate (DNB 2015/2)5 | 137 | 2015 |
| Causes of prolonged hyperbilirubinemia in newborns. Outline steps of investigations and management of it (DNB 2016/2)5+5 | 137 | 2016 |
| Mechanism of action of phototherapy in neonatal hyperbilirubinemia (DNB 2018/2)5 | 137 | 2018 |
| Risk factors for bilirubin toxicity in a newborn (DNB 2021/1)5 | 137 | 2021 |
| Neonate of Rh negative mother - Management (DNB 2021/2)5 | 137 | 2021 |
| Describe the bilirubin metabolism in neonates (DNB 2022/1)5 | 137 | 2022 |
| Describe the bilirubin metabolism (DNB 2024/2)5 | 137 | 2024 |
| Management approach in a baby with prolonged jaundice (DNB 2022/1)5 | 137 | 2022 |
| Management of jaundice associated with breastfeeding (DNB 2022/2)5 | 137 | 2022 |
| Updated recent guidelines for treatment of hyperbilirubinemia in term neonates (DNB 2024/1)5 | 137 | 2024 |
| Evaluation of a baby with persistent conjugated hyperbilirubinemia (DCH 2024/1)5 | 137 | 2024 |
| Principles and adverse effects of phototherapy (DCH 2024/1)5 | 137 | 2024 |
| Different modalities of treatment in neonatal hyperbilirubinemia (DNB 2024/2)5 | 137 | 2024 |
| Anemia in newborn infant (DNB 2007/1)10 | 139 | 2007 |
| A) Anemia of prematurity B) Treatment options for a 3 month old preterm who has Hb of 6gm% (DNB 2015/2)5+5 | 139 | 2015 |
| Causes of Anemia in the Newborn (DNB 1993/1)10, (DNB 2016/1)5 | 139 | 1993 |
| Approach to 2 days old neonate with anemia (DNB 2019/2)6 | 139 | 2019 |
| Hydrops Fetalis (DNB 2003/1)15 | 140 | 2003 |
| Define polycythemia in a newborn. What are the factors predisposing to it? Describe the impact of polycythemia on various systems and their clinical presentation. Describe the management of polycythemia in newborn (DNB 2008/2)10 | 141 | 2008 |
| Outline management of polycythemia (DNB 2016/1)4 | 141 | 2016 |
| Hemorrhagic Disease of The Newborn (DNB 1995/2)15 | 142 | 1995 |
| Outline the classification, clinical manifestations, laboratory findings and differential diagnosis of vitamin K deficiency bleeding (DNB 2012/1)3+3+2+2 | 142 | 2012 |
| Clinical presentation of Vitamin K deficiency in newborn and neonates. Its prevention and management (DNB 2016/2)10 | 142 | 2016 |
| Management of HDN during 1st month of life (DNB 2017/2)4 | 142 | 2017 |
| Hemorrhagic disease of new born (DNB 2022/1)5, (DNB 2022/2)4 | 142 | 2022 |
| What is Hydrops fetalis. Discuss etiology of Non immune hydrops fetalis. What is the management of a case of Non immune hydrops fetalis (DNB 2005/1)2+5+3 | 143 | 2005 |
| Non immune hydrops fetalis (DNB 2003/2)15, (DNB 2007/1)10 | 143 | 2003 |
| Monitoring of Infant of Diabetic Mother (IDM) (DNB 2019/1)5 | 147 | 2019 |
| List the complications seen in infants of diabetic mothers. Describe their pathophysiology.Discuss clinical manifestations and management of infant of diabetic mother (DNB 2023/2)3+3+4 | 147 | 2023 |
| Congenital toxoplasmosis (DNB 1997/2)15 | 149 | 1997 |
| Prevention of Vertically transmitted diseases (DNB 1999/1)15 | 149 | 1999 |
| Outline the clinical presentation, diagnosis and management of a neonate with intrauterine CMV infection (DNB 2011/1)3+4+3 | 149 | 2011 |
| Enumerate the clinical features that indicate presence of a possible intrauterine infection in a neonate. Describe the interpretation of TORCH screen (DNB 2009/2)6+4 | 149 | 2009 |
| Clinical features, investigations and prevention of Congenital Rubella Syndrome (DNB 2010/1)3+3+4 | 149 | 2010 |
| Congenital varicella (DNB 2015/2)4 | 149 | 2015 |
| Treatment and outcome of congenital and neonatal varicella (DNB 2016/2)5 | 149 | 2016 |
| TORCH infections - Prevention (DNB 2021/2)5 | 149 | 2021 |
| Management of a neonate born to VDRL positive mother (DNB 2023/1)5 | 149 | 2023 |
| Antibiotic treatment of Neonatal Meningitis (DNB 1993/2)10 | 149 | 1993 |
| Early diagnosis of Neonatal Septicemia (DNB 1994/2)15 | 149 | 1994 |
| Rapid diagnostic tests in a suspected case of Neonatal Septicemia (DNB 1995/2)10 | 149 | 1995 |
| Infection control in neonatal intensive care (DNB 1998/2)10 | 149 | 1998 |
| Newer modalities in the management of neonatal sepsis (DNB 1999/2)15 | 149 | 1999 |
| Screening tests for neonatal sepsis (DNB 2000/1)15 | 149 | 2000 |
| Prevention of Mother to Child transmission of Hep B (DNB 2000/2)15 | 149 | 2000 |
| Sepsis Screen in neonates (DNB 2006/1)10 | 149 | 2006 |
| Candidiasis in Neonates (DNB 2006/1)10 | 149 | 2006 |
| Adjuvant therapy in Neonatal sepsis (DNB 2006/1)10 | 149 | 2006 |
| Differential Diagnosis of Neonatal sepsis (DNB 2007/1)10 | 149 | 2007 |
| Discuss various adjunct therapies in neonatal sepsis (DNB 2008/1)10 | 149 | 2008 |
| Discuss the predisposing factors, causative agents, methods of diagnosis and treatment of neonatal osteomyelitis (DNB 2009/1)4+6 | 149 | 2009 |
| A 3-day old home delivered boy (Weight 1450g, Gestation 36 wk) is brought to you with abnormal body movements and not accepting feeds. The child is cold to touch and capillary filling time is 5 sec. Outline the immediate, short term and long term management of this child (DNB 2009/1)4+6 | 149 | 2009 |
| Write short notes on: Various adjunctive therapies in the management of overwhelming sepsis in neonates (DNB 2013/2)5 | 149 | 2013 |
| A three days old neonate is brought to the Emergency with history of not accepting feeds for one day. He is found to be lethargic with a HR of 180/min, and capillary filling time of 4 secs and cold extremities. Outline your approach to this neonate along with management of the case. (DNB 2014/1)4+6 | 149 | 2014 |
| Newer diagnostic tests for neonatal sepsis (DNB 2015/1)5 | 149 | 2015 |
| A 4-day old home delivered boy (weight 1350g, Gestation 36 wk) is brought to you with abnormal body movements and non-acceptance of feeds. The child is cold to touch and capillary filling time is 5 seconds. Discuss the diagnosis and management of this child (DNB 2020/1)5+5 | 149 | 2020 |
| Asepsis in NICU (DCH 2023/2)5 | 149 | 2023 |
| Enumerate various indicators related to fetal death (DNB 2025/1)5 | 114 | 2025 |
| Role of antenatal steroids in prevention of preterm morbidity (DNB 2025/1)5 | 116 | 2025 |
| Antenatal screening for trisomy (DNB 2024/2)5 | 117 | 2024 |
| Ultrasound detection of prenatal anomalies (DNB 2025/1)5 | 117 | 2025 |
| Neonatal morbidity with oligohydramnios and polyhydramnios (DNB 2025/1)5 | 117 | 2025 |
| Human leucocyte antigen (HLA) and its role in transplantation (DNB 2025/1)5 | 117 | 2025 |
| Follow-up of a NICU graduate (DNB 2024/2)5 | 119 | 2024 |
| Therapeutic hypothermia in pediatric population (DNB 2024/2)5 | 122 | 2024 |
| Current classification and management of neonatal seizures (DNB 2024/2)5 | 122 | 2024 |
| Changes in Neonatal Resuscitation Program (NRP) India 2024 vs NRP AHA 2020 & implications (DNB 2025/1)5 | 123 | 2025 |
| Cord milking guidelines and controversies (DNB 2024/2)5 | 123 | 2024 |
| Changes in respiratory mechanics in a newborn after birth (DNB 2025/1)5 | 124 | 2025 |
| Pathophysiology of respiratory distress syndrome (RDS) (DNB 2024/2)5 | 126 | 2024 |
| Respiratory support and ventilation strategy for RDS (DNB 2024/2)5 | 126 | 2024 |
| Types of surfactants available for treatment of RDS (DNB 2024/2)5 | 126 | 2024 |
| Fetal intervention for antenatally diagnosed Congenital Diaphragmatic Hernia (DNB 2024/2)5 | 131 | 2024 |
| Embryonic development of diaphragm & congenital diaphragmatic hernia (CDH) (DNB 2025/1)5 | 131 | 2025 |
| Describe bilirubin metabolism (DNB 2024/2)5 | 137 | 2024 |
| Different modalities of treatment in neonatal hyperbilirubinemia (DNB 2024/2)5 | 137 | 2024 |
| Red blood cell exchange transfusion in a newborn (DNB 2025/1)5 | 140 | 2025 |